Differential diagnosis of PRV-infected versus vaccinated pigs using a novel EuNPs-virus antigen probe-based blocking fluorescent lateral flow immunoassay
Publication date: Available online 15 February 2020Source: Biosensors and BioelectronicsAuthor(s): Hui Chen, Xiaoli Zhang, Zhiyuan Jin, Liping Huang, Hanbing Dan, Wei Xiao, Jiajie Liang, Siyi Zou, Yong TangAbstractA novel time-resolved fluorescence blocking lateral flow immunoassay (TRF-BLFIA) was developed for on-site differential diagnosis of pseudorabies virus (PRV)-infected and vaccinated pigs using europium nanoparticles (EuNPs)-labeled virion antigens and high titer PRV gE monoclonal antibodies (PRV gE-mAb). Upon application of a positive serum sample, the specific epitopes of gE protein on the EuNPs-PRV probe were blocked, inhibiting binding to the PRV gE-mAb on the T line, resulting in low or negligible fluorescence signal, whereas when a negative sample was applied, EuNPs-PRV probes would be able to bind the antibody at the T line, leading to high fluorescence signal. Under optimized conditions, TRF-BLFIA provided excellent sensitivity and selectivity. When testing swine clinical samples (n = 356), there was 96.1% agreement between this method and a most widely used commercial gE-ELISA kit. Moreover, our method was rapid (15 min), cost-efficient and easy to operate with simple training, allowing for on-site detection. Thus, TRF-BLFIA could be a practical tool to differentially diagnose PRV-infected and vaccinated pigs.
CONCLUSIONS: At present, lacking an effective vaccine, the prevention and implementation of standard precautions such as chemoprophylaxis, represent the safest strategy to put into practice to eradicate the disease especially for the groups at greater risk as visiting friends and relatives. PMID: 32242538 [PubMed - in process]
Abstract Human papillomavirus (HPV) infection is the primary risk factor for cervical cancer. While the HPV vaccine significantly reduces the risk of HPV infection and subsequent cervical cancer diagnosis, underuse is linked to lack of knowledge of its effectiveness in preventing cervical cancer. The purpose of this study was to evaluate a cancer educational intervention (titled "MOVENUP") to improve knowledge of cervical cancer, HPV, and the HPV vaccine among predominantly African American communities in South Carolina. The MOVENUP cancer educational intervention was conducted among participants residin...
A microbiologist in Germany believes that the use of an updated version of a 100-year-old Tuberculosis vaccine may work as an intermediate treatment for Covid-19. CNN's Frederik Pleitgen reports.
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Jorge A Alfaro-Murillo, Marí L Ávila-Agüero, Meagan C Fitzpatrick, Caroline J Crystal, Luiza-Helena Falleiros-Arlant, Alison P Galvani
CONCLUSIONS: The ability to rapidly identify, propagate, and internationally share our SARS-CoV-2 isolate is an important step in collaborative scientific efforts to deal effectively with this international public health emergency by developing better diagnostic procedures, vaccine candidates, and antiviral agents. PMID: 32237278 [PubMed - as supplied by publisher]
Authors: Valentino S, Suit L Abstract Background: The community college student is not currently armed with the resources or prevention information regarding influenza. Less than twenty percent of the college population receives influenza immunization annually.Purpose: The purpose of the project was to evaluate if an evidenced-based influenza and vaccine education intervention will affect nursing students' intent to vaccinate for influenza by increasing knowledge of the influenza vaccine using Zingg and Siegrist's Knowledge Scale.Methods: Participants were recruited voluntarily from their attendance at orientation ...
Dr. Tom Inglesby, the director of the Center For Health Security of the Johns Hopkins School of Public Health,joins "CBS Evening News" with more on the coronavirus vaccine and strategies to practice while social distancing.
Dr. Tom Inglesby, the director of the Johns Hopkins Center for Health Security, on the benefit of masks for the general public and a possible vaccine.